Login Register Cart 0
Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Effects of Cycloastragenol on Alzheimer's Disease in Rats by Reducing Oxidative Stress, Inflammation, and Apoptosis

Author(s): Kadi M. Alharbi, Shahad A. Alshehri, Wasayf A. Almarwani, Khulud K. Aljohani, Ajwan Z. Albalawi, Areej S. Alatawi, Shekha M. Al-Atwi, Lama S. Alhwyty, Hanan M. Hassan and Mohammed M.H. Al-Gayyar*

Volume 21, Issue 2, 2024

Published on: 17 May, 2024

Page: [141 - 154] Pages: 14

DOI: 10.2174/0115672050315334240508162754

Price: $65

conference banner
Abstract

Background: As individuals age, they may develop Alzheimer's disease (AD), which is characterized by difficulties in speech, memory loss, and other issues related to neural function. Cycloastragenol is an active ingredient of Astragalus trojanus and has been used to treat inflammation, aging, heart disease, and cancer.

Objectives: This study aimed to explore the potential therapeutic benefits of cycloastragenol in rats with experimentally induced AD. Moreover, the underlying molecular mechanisms were also evaluated by measuring Nrf2 and HO-1, which are involved in oxidative stress, NFκB and TNF-α, which are involved in inflammation, and BCL2, BAX, and caspase-3, which are involved in apoptosis.

Methods: Sprague-Dawley rats were given 70 mg/kg of aluminum chloride intraperitoneally daily for six weeks to induce AD. Following AD induction, the rats were given 25 mg/kg of cycloastragenol daily by oral gavage for three weeks. Hippocampal sections were stained with hematoxylin/ eosin and with anti-caspase-3 antibodies. The Nrf2, HO-1, NFκB, TNF-α, BCL2, BAX, and caspase-3 gene expressions and protein levels in the samples were analyzed.

Results: Cycloastragenol significantly improved rats' behavioral test performance. It also strengthened the organization of the hippocampus. Cycloastragenol significantly improved behavioral performance and improved hippocampal structure in rats. It caused a marked decrease in the expression of NFκB, TNF-α, BAX, and caspase-3, which was associated with an increase in the expression of BCL2, Nrf2, and HO-1.

Conclusion: Cycloastragenol improved the structure of the hippocampus in rats with AD. It enhanced the outcomes of behavioral tests, decreased the concentration of AChE in the brain, and exerted antioxidant and anti-inflammatory effects. Antiapoptotic effects were also noted, leading to significant improvements in cognitive function, memory, and behavior in treated rats.

« Previous
[1]
Breijyeh Z, Karaman R. Comprehensive review on Alzheimer’s Disease: Causes and treatment. Molecules 2020; 25(24): 5789.
[http://dx.doi.org/10.3390/molecules25245789] [PMID: 33302541]
[2]
Zhang Y, Kiryu H. Identification of oxidative stress-related genes differentially expressed in Alzheimer’s disease and construction of a hub gene-based diagnostic model. Sci Rep 2023; 13(1): 6817.
[http://dx.doi.org/10.1038/s41598-023-34021-1] [PMID: 37100862]
[3]
Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT. The epidemiology of alzheimer’s disease modifiable risk factors and prevention. J Prev Alzheimers Dis 2021; 8(3): 1-9.
[http://dx.doi.org/10.14283/jpad.2021.15] [PMID: 34101789]
[4]
Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer’s disease: Targeting the Cholinergic System. Curr Neuropharmacol 2016; 14(1): 101-15.
[http://dx.doi.org/10.2174/1570159X13666150716165726] [PMID: 26813123]
[5]
Wang R, Reddy PH. Role of glutamate and NMDA receptors in alzheimer’s disease. J Alzheimers Dis 2017; 57(4): 1041-8.
[http://dx.doi.org/10.3233/JAD-160763] [PMID: 27662322]
[6]
Bagalagel A, Diri R, Noor A, et al. The therapeutic effects of cycloastragenol in ulcerative colitis by modulating SphK/ MIP-1α/miR-143 signalling. Basic Clin Pharmacol Toxicol 2022; 131(5): 406-19.
[http://dx.doi.org/10.1111/bcpt.13788] [PMID: 36029292]
[7]
Yu Y, Zhou L, Yang Y, Liu Y. Cycloastragenol: An exciting novel candidate for age-associated diseases (Review). Exp Ther Med 2018; 16(3): 2175-82.
[http://dx.doi.org/10.3892/etm.2018.6501] [PMID: 30186456]
[8]
Güven L, Erturk A, Miloğlu FD, Alwasel S, Gulcin İ. Screening of antiglaucoma, antidiabetic, anti-alzheimer, and antioxidant activities of Astragalus alopecurus pall—analysis of phenolics profiles by LC-MS/MS. Pharmaceuticals (Basel) 2023; 16(5): 659.
[http://dx.doi.org/10.3390/ph16050659] [PMID: 37242442]
[9]
Dong Q, Li Z, Zhang Q, Hu Y, Liang H, Xiong L. Astragalus mongholicus Bunge (Fabaceae): Bioactive compounds and potential therapeutic mechanisms against Alzheimer’s disease. Front Pharmacol 2022; 13: 924429.
[http://dx.doi.org/10.3389/fphar.2022.924429] [PMID: 35837291]
[10]
Bahaeddin Z, Yans A, Khodagholi F, Sahranavard S. Dietary supplementation with Allium hirtifolium and/or Astragalus hamosus improved memory and reduced neuro-inflammation in the rat model of Alzheimer’s disease. Appl Physiol Nutr Metab 2018; 43(6): 558-64.
[http://dx.doi.org/10.1139/apnm-2017-0585] [PMID: 29262273]
[11]
Wankhede NL, Kale MB, Upaganlawar AB, et al. Involvement of molecular chaperone in protein-misfolding brain diseases. Biomed Pharmacother 2022; 147: 112647.
[http://dx.doi.org/10.1016/j.biopha.2022.112647] [PMID: 35149361]
[12]
Ajmal MR. Protein misfolding and aggregation in proteinopathies: Causes, mechanism and cellular response. Diseases 2023; 11(1): 30.
[http://dx.doi.org/10.3390/diseases11010030] [PMID: 36810544]
[13]
Samman WA, Selim SM, El Fayoumi HM, El-Sayed NM, Mehanna ET, Hazem RM. Dapagliflozin ameliorates cognitive impairment in aluminum-chloride-induced alzheimer’s disease via modulation of AMPK/mTOR, oxidative stress and glucose metabolism. Pharmaceuticals (Basel) 2023; 16(5): 753.
[http://dx.doi.org/10.3390/ph16050753] [PMID: 37242536]
[14]
Abd El-Aziz NMA, Shehata MG, Alsulami T, et al. Characterization of orange peel extract and its potential protective effect against aluminum chloride-induced alzheimer’s disease. Pharmaceuticals (Basel) 2022; 16(1): 12.
[http://dx.doi.org/10.3390/ph16010012] [PMID: 36678510]
[15]
Bayomi HS, Elsherbiny NM, El-Gayar AM, Al-Gayyar MMH. Evaluation of renal protective effects of inhibiting TGF-β type I receptor in a cisplatin-induced nephrotoxicity model. Eur Cytokine Netw 2013; 24(4): 139-47.
[http://dx.doi.org/10.1684/ecn.2014.0344] [PMID: 24590376]
[16]
Alshehri A, Albuhayri A, Alanazi M, et al. Effects of Echinacoside on Ehrlich Carcinoma in rats by targeting proliferation, hypoxia and inflammation. Cureus 2023; 15(10): e46800.
[http://dx.doi.org/10.7759/cureus.46800] [PMID: 37822691]
[17]
Alfair BM, Jabarti AA, Albalawi SS, Khodir AE, Al-Gayyar MM. Arctiin inhibits inflammation, fibrosis, and tumor cell migration in rats with ehrlich solid carcinoma. Cureus 2023; 15(9): e44987.
[http://dx.doi.org/10.7759/cureus.44987] [PMID: 37701157]
[18]
Albalawi AZ, Alatawi AS, Al-Atwi SM. Echinacoside ameliorates hepatic fibrosis and tumor invasion in rats with thioacetamide-induced hepatocellular carcinoma. Biomol Biomed 2024; 2024: 10367.
[http://dx.doi.org/10.17305/bb.2024.10367]
[19]
Al-Gayyar MMH, Abbas A, Hamdan AM. Chemopreventive and hepatoprotective roles of adiponectin (SULF2 inhibitor) in hepatocelluar carcinoma. Biol Chem 2016; 397(3): 257-67.
[http://dx.doi.org/10.1515/hsz-2015-0265] [PMID: 26733159]
[20]
Alatawi YF, Alhablani MA, Al-Rashidi FA, et al. Garcinol-attenuated Gastric Ulcer (GU) experimentally induced in rats via affecting inflammation, cell proliferation, and DNA polymerization. Cureus 2023; 15(8): e43317.
[http://dx.doi.org/10.7759/cureus.43317] [PMID: 37577271]
[21]
Alghamdi MA, Khalifah TA, Alhawati HS, et al. Antitumor activity of ferulic acid against ehrlich solid carcinoma in rats via affecting hypoxia, oxidative stress and cell proliferation. Cureus 2023; 15(7): e41985.
[http://dx.doi.org/10.7759/cureus.41985] [PMID: 37465088]
[22]
Alshehri SA, Almarwani WA, Albalawi AZ, et al. Role of arctiin in fibrosis and apoptosis in experimentally induced hepatocellular carcinoma in rats. Cureus 2024; 16(1): e51997.
[http://dx.doi.org/10.7759/cureus.51997] [PMID: 38205087]
[23]
Kandimalla R, Vallamkondu J, Corgiat EB, Gill KD. Understanding aspects of aluminum exposure in Alzheimer’s Disease Development. Brain Pathol 2016; 26(2): 139-54.
[http://dx.doi.org/10.1111/bpa.12333] [PMID: 26494454]
[24]
Tönnies E, Trushina E. Oxidative stress, synaptic dysfunction, and alzheimer’s disease. J Alzheimers Dis 2017; 57(4): 1105-21.
[http://dx.doi.org/10.3233/JAD-161088] [PMID: 28059794]
[25]
He F, Ru X, Wen T. NRF2, a transcription factor for stress response and beyond. Int J Mol Sci 2020; 21(13): 4777.
[http://dx.doi.org/10.3390/ijms21134777] [PMID: 32640524]
[26]
Duvigneau JC, Esterbauer H, Kozlov AV. Role of heme oxygenase as a modulator of heme-mediated pathways. Antioxidants 2019; 8(10): 475.
[http://dx.doi.org/10.3390/antiox8100475] [PMID: 31614577]
[27]
De Plano LM, Calabrese G, Rizzo MG, Oddo S, Caccamo A. The role of the transcription factor Nrf2 in alzheimer’s disease: Therapeutic opportunities. Biomolecules 2023; 13(3): 549.
[http://dx.doi.org/10.3390/biom13030549] [PMID: 36979483]
[28]
Liu R, Yang J, Li Y, Xie J, Wang J. Heme oxygenase-1: The roles of both good and evil in neurodegenerative diseases. J Neurochem 2023; 167(3): 347-61.
[http://dx.doi.org/10.1111/jnc.15969] [PMID: 37746863]
[29]
Chen T, Li Z, Li S, et al. Cycloastragenol suppresses M1 and promotes M2 polarization in LPS-stimulated BV-2 cells and ischemic stroke mice. Int Immunopharmacol 2022; 113(Pt A): 109290.
[http://dx.doi.org/10.1016/j.intimp.2022.109290] [PMID: 36252498]
[30]
Wang G, Ma C, Chen K, et al. Cycloastragenol attenuates osteoclastogenesis and bone loss by targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, calcium, and NFATc1 pathways. Front Pharmacol 2022; 12: 810322.
[http://dx.doi.org/10.3389/fphar.2021.810322] [PMID: 35126144]
[31]
Judd JM, Jasbi P, Winslow W, et al. Inflammation and the pathological progression of Alzheimer’s disease are associated with low circulating choline levels. Acta Neuropathol 2023; 146(4): 565-83.
[http://dx.doi.org/10.1007/s00401-023-02616-7] [PMID: 37548694]
[32]
Sivamaruthi BS, Raghani N, Chorawala M, et al. NF-κB pathway and its inhibitors: A promising frontier in the management of alzheimer’s disease. Biomedicines 2023; 11(9): 2587.
[http://dx.doi.org/10.3390/biomedicines11092587] [PMID: 37761028]
[33]
Jin J, Guang M, Li S, et al. Immune-related signature of periodontitis and Alzheimer’s disease linkage. Front Genet 2023; 14: 1230245.
[http://dx.doi.org/10.3389/fgene.2023.1230245] [PMID: 37849501]
[34]
Li M, Li S, Dou B, et al. Cycloastragenol upregulates SIRT1 expression, attenuates apoptosis and suppresses neuroinflammation after brain ischemia. Acta Pharmacol Sin 2020; 41(8): 1025-32.
[http://dx.doi.org/10.1038/s41401-020-0386-6] [PMID: 32203080]
[35]
Ren Y, Li H, Yao J, et al. Application quantitative proteomics approach to identify differentially expressed proteins associated with cardiac protection mediated by cycloastragenol in acute myocardial infarction rats. J Proteomics 2020; 222: 103691.
[http://dx.doi.org/10.1016/j.jprot.2020.103691] [PMID: 32068187]
[36]
Haiyan H, Yiyu W, Yihui Z, et al. Effect of Qingxinkaiqiao compound on cortical mRNA expression of the apoptosis-related genes Bcl-2, BAX, caspase-3, and Aβ in an Alzheimer’s disease rat model. J Tradit Chin Med 2016; 36(5): 654-62.
[http://dx.doi.org/10.1016/S0254-6272(16)30086-3] [PMID: 29933535]
[37]
Su JH, Satou T, Anderson AJ, Cotman CW. Up-regulation of Bcl-2 is associated with neuronal DNA damage in Alzheimerʼs disease. Neuroreport 1996; 7(2): 437-40.
[http://dx.doi.org/10.1097/00001756-199601310-00015] [PMID: 8730800]
[38]
Callens M, Kraskovskaya N, Derevtsova K, et al. The role of Bcl-2 proteins in modulating neuronal Ca2+ signaling in health and in Alzheimer’s disease. Biochim Biophys Acta Mol Cell Res 2021; 1868(6): 118997.
[http://dx.doi.org/10.1016/j.bbamcr.2021.118997] [PMID: 33711363]
[39]
Berridge MJ. Vitamin D, reactive oxygen species and calcium signalling in ageing and disease. Philos Trans R Soc Lond B Biol Sci 2016; 371(1700): 20150434.
[http://dx.doi.org/10.1098/rstb.2015.0434] [PMID: 27377727]
[40]
Ureshino RP, Bertoncini CR, Fernandes MJS, et al. Alterations in calcium signaling and a decrease in Bcl-2 expression: Possible correlation with apoptosis in aged striatum. J Neurosci Res 2010; 88(2): 438-47.
[http://dx.doi.org/10.1002/jnr.22214] [PMID: 19774672]
[41]
Rohn TT, Vyas V, Hernandez-Estrada T, Nichol KE, Christie LA, Head E. Lack of pathology in a triple transgenic mouse model of Alzheimer’s disease after overexpression of the anti-apoptotic protein Bcl-2. J Neurosci 2008; 28(12): 3051-9.
[http://dx.doi.org/10.1523/JNEUROSCI.5620-07.2008] [PMID: 18354008]
[42]
Khezri MR, Ghasemnejad-Berenji M, Moloodsouri D. The PI3K/AKT signaling pathway and caspase-3 in alzheimer’s disease: Which one is the beginner? J Alzheimers Dis 2023; 92(2): 391-3.
[http://dx.doi.org/10.3233/JAD-221157] [PMID: 36776071]
[43]
Goel P, Chakrabarti S, Goel K, Bhutani K, Chopra T, Bali S. Neuronal cell death mechanisms in Alzheimer’s disease: An insight. Front Mol Neurosci 2022; 15: 937133.
[http://dx.doi.org/10.3389/fnmol.2022.937133] [PMID: 36090249]
[44]
Hong H, Xiao J, Guo Q, et al. Cycloastragenol and Astragaloside IV activate telomerase and protect nucleus pulposus cells against high glucose-induced senescence and apoptosis. Exp Ther Med 2021; 22(5): 1326.
[http://dx.doi.org/10.3892/etm.2021.10761] [PMID: 34630680]
[45]
Szabo NJ. Dietary safety of cycloastragenol from Astragalus spp.: Subchronic toxicity and genotoxicity studies. Food Chem Toxicol 2014; 64: 322-34.
[http://dx.doi.org/10.1016/j.fct.2013.11.041] [PMID: 24316212]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy